Private Equity

The national safety giant's latest Houston acquisition strengthens its market hold, integrates deep expertise, and expands its all-in-one service model.

A new giant enters the AI arena. Brookfield launches Radiant to build global 'AI factories,' challenging cloud titans and fueling the race for sovereign AI.

National home services leader On Track Partners acquires a beloved Wisconsin firm, signaling a major Midwest expansion fueled by a private equity trend.

A new report offers cities a framework to fight climate change, housing unaffordability, and economic inequity with integrated, equitable strategies.

Director Valerio Zanoli's new documentary doesn't just raise awareness; its profits build homes, challenging how we fight the global housing crisis.

As millions of solar panels near retirement, one Tennessee facility is turning a potential waste crisis into a sustainable manufacturing success story.

Tradewinds Universal aims to consolidate the fragmented $8B adult club scene with Peppermint Hippo, but regulatory hurdles and market risks loom large.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

A 20-year fight to save Nova Scotia salmon from acid rain is now a certified climate technology, attracting major investment and creating a new model for conservation.

Fort Worth Plastic Surgery's new partnership with a PE-backed group highlights a major industry shift, raising questions about growth, autonomy, and patient care.

The merger, backed by private equity, creates a dominant force in higher education services, aiming to tackle digital transformation and student success.

Lithium developer Stardust Power partners with a Pentagon-aligned group, a critical move to reduce foreign reliance and fuel the U.S. energy transition.

Hunt Energy Network acquires the massive Fort Duncan battery, boosting its Texas portfolio to 420MW and signaling an aggressive expansion in the booming ERCOT market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The powertrain giant crushed market expectations with a 29% revenue surge in 2025, fueled by heavy-duty engines, while eyeing a global and green future.

After a massive divestiture, Brightstar Lottery slashes debt, rewards investors, and sets its sights on digital expansion in Italy and Brazil.